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The role of evidence and the expert in contemporary processes of governance: 
the case of opioid substitution treatment policy in England 
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treatment 
 
Abstract 
Background 
This paper is based on research examining stakeholder involvement in substitution 
treatment policy which was undertaken as part of the EU funded FP7 ALICE-RAP 
(Addictions and Lifestyles in Contemporary Europe – Reframing Addictions Project).  
In England, the research coincided with a policy shift towards a recovery orientated 
drug treatment framework and a heated debate surrounding the role of substitute 
prescribing.  The study aimed to explore the various influences on the development of 
the new „recovery‟ policy from the perspectives of the key stakeholders involved. 
Methods 
The paper is based on documentary analyses and key informant interviews with a 
range of stakeholders, including representatives of user organisations, treatment 
providers, civil servants, and members of expert committees.  
Results 
Drawing on the theoretical insights offered by Backstrand‟s „civic science‟ 
framework, the changing role of evidence and the position of experts in the processes 
of drugs policy governance are explored.  „Evidence‟ was used to problematise the 
issue of substitution treatment and employed to legitimise, justify and construct 
arguments around the possible directions of policy and practice.  Conflicting beliefs 
about drug treatment and about motivation for policy change emerge in the 
argumentation, illustrating tensions in the governance of drug treatment and the power 
differentials separating different groups of stakeholders. Their role in the production 
of evidence also illustrates issues of power regarding the definition and development 
of „usable knowledge‟. There were various attempts at greater representation of 
different forms of evidence and participation by a wider group of stakeholders in the 
debates surrounding substitution treatment.  However, key national and international 
experts and the appointment of specialist committees continued to play dominant 
roles in building consensus and translating scientific evidence into policy discourse. 
 
*Manuscript
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Conclusion 
Substitution treatment policy has witnessed a challenge to the dominance of 
„scientific evidence‟ within policy decision making, but in the absence of alternative 
evidence with an acceptable credibility and legitimacy base, traditional notions of 
what constitutes evidence based policy persist and there is a continuing lack of 
recognition of „civic science‟. 
 
 
 
 
Page 4 of 32
Ac
ce
pte
d M
an
us
cri
pt
3 
 
The role of evidence and the expert in contemporary processes of governance: 
the case of opioid substitution treatment policy in England 
 
Introduction 
The rhetoric of evidence-based policy and practice emerged strongly and gained 
currency across policy domains throughout the Labour government‟s period of office 
in the UK (1997-2010). It occurred in parallel with a drive towards de-centralisation 
of policy (or localisation) and the establishment of a variety of new networks and 
structures, such as partnerships, intended to facilitate the implementation of evidence 
based policy at local level and widen participation in governance (Newman, 2001). 
Within a rational knowledge-driven model of the relationship between policy and 
evidence, „scientific‟ evidence was offered as the appropriate foundation for 
legitimising policy options at all levels. Scientific evidence was held to derive from 
particular forms of research with randomised controlled trials (RCTs), meta-analyses, 
systematic reviews, epidemiological analyses and „modelling‟ studies being valued 
above research adopting what was seen as less rigorous methodologies. In this model, 
the „expert‟, as interpreter (and sometimes the producer) of evidence is at the 
forefront. 
However, the notion of „scientific‟ or research based evidence as the dominant factor 
in policy decisions has long been criticised as divorced from the realities of policy 
making (Pawson and Tilley, 1997) and more recently questions have been raised 
regarding how some particular forms of knowledge come to be regarded as „evidence‟ 
while other forms are rejected or seen to be of lesser value and, therefore, less 
deserving of policy attention (Williams and Glasby, 2010). In particular, as local 
decision makers are increasingly responsible for policy and practice development, the 
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question of what kind of evidence or knowledge is appropriate and useful in deciding 
on local issues becomes especially pertinent. The localism agenda has helped to create 
new layers of stakeholders concerned with the production and use of evidence to 
develop locally appropriate policy and implement „best practice‟. Local service 
commissioners, for example, are expected to conduct regular needs assessments and 
to base decisions on service provision on evidence of local needs and service 
providers are expected to provide evidence of outcomes and of success in meeting set 
targets. As a result, an increasing number of stakeholders have become involved in 
policy debates and governance networks and have drawn on evidence to argue their 
case.  
A parallel development has been the call for a broader notion of knowledge-based 
policy and practice, which includes the experiential knowledge of practitioners and 
the lived experiences of service users (Glasby and Beresford, 2006), and stretches 
even to the inclusion of „citizens‟ (Backstrand, 2004a). This highlights a challenge to 
the traditional dominance of scientists, experts and policy makers as the main 
stakeholders within the science-policy interface. Backstrand (2004a) points out that, 
although top down models of the science-policy relationship grant power to networks 
of scientific experts, specialists and bureaucrats, the boundaries between scientific 
evidence and non-scientific evidence, expert and lay knowledge, global and local 
knowledge are not clear cut and can be negotiated in the course of the policy process. 
The production, source and use of evidence (or knowledge) thus become a core 
strategic element within governance networks.  
The changing relationship between scientific evidence, expert, professional and lay 
knowledge has coincided with the rise of a „civic science‟ framework which helps to 
Page 6 of 32
Ac
ce
pte
d M
an
us
cri
pt
5 
 
conceptualise the „various attempts to increase public participation in the production 
and use of scientific knowledge‟ (Backstrand, 2004a, p. 24). Within this perspective, 
citizens have a stake in the science-policy nexus. Backstrand (2004a) argues that the 
science-policy interface requires reframing as a triangular interaction between 
scientific experts, policy makers and citizens. She points to the different agendas 
relating to democratizing scientific expertise including increasing public and 
stakeholder participation in science; complementing scientific with alternative forms 
of knowledge; ensuring accountability and transparency within science; and 
transforming the hierarchical relationship between scientific expert and lay non 
scientists (Backstrand, 2004b, p. 656). These processes have been examined 
principally in the field of sustainability science (ie. climate change, management of 
natural resources and bio-safety) but provide a framework for examining trends in 
other policy domains. However, in many policy areas, the framework requires 
adaptation to account for the different role of „citizens‟ within the debates.  Within 
drugs policy and the substitution treatment debate more specifically, the wider public 
does not have the same interest or stake as they do within the environmental science 
debates. Nor do they play a role in the production and use of evidence other than as 
the subjects of research or as the recipients of „evidence based‟ policy and practice or 
as the target group for media information and professional messages. „Citizens‟ 
therefore need to be defined widely to include, for example, professional groups, non-
governmental organisations (NGOs) or user groups, as well as the general public. 
Drawing on these theoretical insights, we consider the changing role of evidence and 
the position of experts in drugs policy governance in England.  
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The rhetoric of evidence-based policy and practice has been emphasised in the drugs 
field for many years. The „gold standard‟ is systematic reviews of mainly RCTs 
conducted by the Drugs and Alcohol Group of the Cochrane Collaboration. The 
Cochrane Collaboration is an international, independent, non-profit organisation 
funded by various sources including governments, universities, hospital trusts and 
charities.  In addition to producing systematic reviews, Cochrane scientists engage in 
advocacy for evidence-based decision making.  Day (2013, p.19) argues that this form 
of review „strives to present the whole picture, and to do so in a way that invites 
critique and improvement.  This puts vested interests to one side and can only benefit 
the consumer‟.  Although the drugs field is dominated by the „expert‟, top down 
model of production and use of scientific evidence in the policy process, we can see 
examples of widening participation and representation; for instance, through 
consultation exercises and consensus conferences arranged in an attempt to reach 
agreement around the future direction of policy.  Similarly, a wide range of 
stakeholders provided evidence to the recent House of Commons Home Affairs 
Committee inquiry into drug policy, including the traditional medical „experts‟ as well 
as advocacy and activist organisations, think tanks, a range of treatment providers, 
academics, pharmaceutical companies, user groups and users representing themselves, 
including the recovering celebrity, Russell Brand who provided evidence in person as 
a key witness (Home Affairs Committee, 2012). There is some indication, therefore, 
of broadening out towards a more inclusive concept of „evidence‟ and „expertise‟. As 
MacGregor (2012, p. 14) argues, the evidence has increased in both volume and 
complexity over time which relates to the increase in the stakeholders involved and 
the growing public attention to drugs issues. 
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However, at the heart of stakeholders‟ discourses lie different types of evidence, 
produced and disseminated by these groups. Boundaries or borders may be 
established between scientific and „lay‟ knowledge within the policy space through 
the maintenance of the legitimacy, credibility and authority of scientific knowledge 
(Gieryn, 1995). But even among experts differences of opinion arise over the 
significance, interpretation and sufficiency of the evidence; sometimes the same body 
of evidence is used to advocate different policy solutions to a perceived problem. 
Within this dynamic, some expert stakeholders are able to exert power and influence 
in determining what evidence gets used, how it is used and when it is used.  They also 
decide how different types of evidence and sources are balanced against one another. 
Other voices have to struggle for policy attention and some may be excluded 
altogether. As Backstrand (2004a, p. 30) states, „Scientific knowledge is in many 
areas provisional, uncertain and incomplete. Thus, competing expert knowledge has 
in many instances given rise to a battle between experts and counter experts‟. The 
notion of „civic science‟ is useful, therefore, to understand how various types of 
„evidence‟ have been employed in recent drugs policy debates and to consider the 
extent to which the traditional expert scientist-policy bureaucrat dominance has been 
challenged and, possibly, opened up by stakeholders who both question the science 
and produce alternative forms of evidence. Recent debates between stakeholders 
surrounding the role of „recovery‟ in drugs treatment, particularly regarding the place 
of opioid substitute prescribing in treatment policy provides a window into examining 
both the nature and role of evidence and the role of „experts‟ in influencing policy.  
The debate on opioid substitution treatment has raised questions regarding the concept 
of recovery and in particular has focussed attention on recovery goals. It has tended to 
polarise arguments into two camps – those who advocate abstinence as the goal and 
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those who stress the need for harm reduction approaches (including substitution 
treatment). In reality, the issues are more complex and many commentators have 
opposed the view that harm reduction and abstinence are mutually exclusive (cf. 
special section in Drugs: education, prevention and policy, 2012) 
This paper will explore the participation of stakeholders (including citizens) in the 
production and use of scientific knowledge/evidence in the shift towards a recovery 
based framework for drug treatment policy. It will examine how advocates or „policy 
entrepreneurs‟, in alliance with research advocates, used „new‟ knowledge to 
challenge the status quo in drug treatment policy.  It will be argued that the area of 
substitution treatment policy has witnessed a challenge to the dominance of „scientific 
evidence‟ to policy decision making but in the absence of alternative evidence with an 
acceptable credibility and legitimacy base, traditional notions of what constitutes 
evidence based policy persist and there is a continuing  lack of recognition of „civic 
science‟. In short, the expert still plays a central role in translating scientific evidence 
into policy discourse through a number of mediums, such as expert committees, 
although inclusive approaches – such as consultations – have opened doors to some 
extent to other voices and other forms of evidence. The analysis indicates that, despite 
the new policy governance structures and processes espoused by recent governments 
and visible to varying degrees across health and social care domains, with regard to 
drug substitution treatment issues, control has remained largely under central 
authorities and their traditional „expert‟ advisors, drawing on accepted forms of 
scientific evidence rather than being devolved down to professional networks or wider 
groups of stakeholders.   
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Research Design and Methodology  
Substitution treatment was chosen as the topic for study because it has been a highly 
contested area within drug policy governance and highlights the divergent interests 
and stakeholders in this field over time (see Thom et al, 2013 for further background 
to the case study).  Following the work of Brugha and Varasovsky (2000) on 
stakeholder analysis, a broad definition of „stakeholder‟ was adopted: an individual, 
group or network of people involved with, or with interests in, or affected by a 
particular area of activity or a particular policy. Stakeholders for this study were 
classified into the following broad categories: policy makers (includes civil servants, 
career bureaucrats, and politicians); advocacy organisations (includes interest/pressure 
groups, drug user organisations, family/carer organisations); professional and/or 
scientific associations/societies; treatment sector (includes public/private, non 
statutory/statutory and mutual aid); researchers/scientists; and economic stakeholders 
(includes pharmaceutical industry, and „social enterprises‟ or businesses with 
primarily social objectives).   
Stakeholders in the area of substitution treatment policy were identified initially from 
a review of policy documents, relevant literature and the personal knowledge of the 
authors. The majority of the documents consulted were written or published within 
the last ten years from 2001 to the present day.  The focus of the documentary 
analysis was to identify key stakeholders, to examine the discourse surrounding the 
role of substitution treatment over time; to examine the contribution and influence of 
key stakeholders in the production and dissemination of the documentation, and to 
develop appropriate question domains for the interviews. Starting with selection from 
the initial list generated from documentation, interviewees were asked to identify 
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other groups or individuals who were seen as important players in the recovery 
debate. Selection of interviewees aimed to include most (if not all) of the categories 
listed above but was determined in part by purposive sampling to cover themes and 
explore theoretical insights. The stakeholders selected for interview were also defined 
by their knowledge, experience, seniority and position within their organisations. 
Although some of the stakeholders also play key roles at regional and local levels of 
policy and practice, the majority of those interviewed operate at the national level of 
policy-making. A total of 20 interviews were conducted; two with policy-makers, six 
with representatives from advocacy organisations, five with representatives from the 
treatment sector, five with researchers/scientists, and two with economic stakeholders.  
A qualitative approach was chosen as best suited to gaining insight into the different 
ways in which individuals understand and interpret the world in which they live – in 
this case, their relationship with the substitution treatment arena (Maxwell, 2012). The 
purpose of the interviews was to provide in-depth understanding of the more recent 
shifts in the development of stakeholder‟s interest and influence, particularly in the 
movement towards a recovery-based framework in drugs policy.  The interviews were 
semi-structured but used open ended discussion to allow interviewees to express their 
thoughts and experiences in their own way (Rubin and Rubin, 2011). The discussion 
focused on the activities and influence of the various stakeholders on policy 
development, the impact of policy change on stakeholders‟ positions and influence in 
the policy space and on the dynamics between stakeholder groups and on the factors 
which influence their activities. Depending on the interviewee, questions on 
„evidence‟ were sometimes, but not always, asked directly. However, in most cases, 
issues regarding research and evidence emerged in the course of the discussion, for 
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instance, in accounts about how organisations and individuals presented their case for 
or against substitution treatment and from broad questions such as, „What factors have 
been driving policy on substitution treatment over the last 10 years?‟  
The interviews were conducted from January to September 2012, took place either in 
the respondent‟s place of work, at the university or by telephone, and lasted between 
one and two hours.  All interviews were recorded and transcribed.  Respondents were 
guaranteed confidentiality and anonymity.  All identifiers such as details about the 
organisation, agency, or department of the respondents have been removed in order to 
ensure that information is non-attributable. 
At the end of the fieldwork, all interview transcripts and notes were read carefully and 
systematically.  All themes and categories emerging from the data were noted and 
coded on the transcripts. Some themes had been derived from existing theory, 
literature, and the documents and had been covered systematically within the 
interviews, while others had been generated spontaneously and were subsequently 
developed inductively during analysis. We began with our initial thematic framework 
but, in examining the topic of evidence and stakeholding, the themes were largely 
those emerging from interviewees‟ accounts.  
 
Challenging the consensus in treatment policy 
MacGregor (2011) argues that research has tended to have had impact where there is a 
direct link to the policy market and where a window of opportunity is open, for 
example a particular „crisis‟ or change of government.  She traces how research 
helped to frame the harm reduction approach adopted in British drugs policy in the 
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late 1980s and then helped to construct the criminalisation of drug policy from the 
mid 1990s onwards.  Within the drug treatment debate, evidence showing the crime 
reduction and public health benefits of substitution treatment was used to argue for its 
expansion. The development of the harm reduction approach was underpinned by „an 
alliance of evidence and activism leading to radical policy change‟ (MacGregor, 
2011, p. 44). The International Harm Reduction Association (IHRA), which was 
fundamental to these developments, deliberately promoted a form of „civic science‟ 
which was characterised by a fusion of research, policy and legal analyses, knowledge 
exchange between a wide range of stakeholders and advocacy work around harm 
reduction and drug policy reform. Byrne and Albert (2009, p. 111) describe the 
opportunities afforded by the IHRA to users and user groups as “a key ideological 
shift from an exclusively public health to a more inclusive human rights focus” which 
allows for the incorporation of evidence based on „lived experience‟.   
However, this does not meant that there were no challenges to the place of methadone 
maintenance within drug treatment during this particular period.  There is a long 
history of conflict regarding the role of substitute prescribing between those who 
advocate a harm reduction approach and those who promote abstinence only 
treatment (see Mold, 2008 for an indepth historical analysis).  In 1996 in light of 
criticism of maintenance prescribing, the Polkinghorne Review of Treatment Task 
Force collected evidence supporting its effectiveness which led to the funding of the 
longitudinal National Treatment Outcomes Research Study (NTORS) (MacGregor 
2011). Based on the reviews of evidence, the consensus was that „treatment works‟, 
and the importance of harm reduction within drug treatment, was re-affirmed 
(Department of Health, 1996). 
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In 2001, the National Treatment Agency for Substance Misuse (NTA) was set up as a 
special health authority within the National Health Service (NHS) to improve 
treatment for drug misuse in England. With the establishment of the NTA, the 
allocation of unprecedented amounts of funding for drug treatment, and mounting 
research evidence for the cost effectiveness of treatment, increasing numbers of drug 
users were prescribed methadone on a maintenance basis. A director of an advocacy 
organisation described the expansion of bureaucracy for drug treatment policy and 
how the evidence base around substitute prescribing was used to legitimate its 
increase: 
“It sets up the National Treatment Agency...so you have a bureaucratic system 
with targets, able and being held accountable...that‟s how we‟ve got that 
dynamic for prescribing and its expansion.  You‟ve got the legitimacy through 
the evidence base, you‟ve got the money coming into the system and a means 
to dispense it, and you‟ve got performance targets...so how do you deliver 
interventions quickly?  Substitute prescribing is stuff that you can do fairly 
rapidly.” 
The comment highlights the role of research (scientific evidence) in legitimating 
government action. This positioning of scientific evidence within established policy 
approaches and bureaucratic systems makes it difficult to challenge and the more vital 
it becomes to the raison d‟etre of the establishment, the more likely it is to provide a 
basis for the production of similar types of research linked to the function of the 
established system and to achieving its targets. Following the set up of the NTA, the 
power bestowed by the established system on large stakeholders who subscribed to 
substitution treatment was reflected on by a stakeholder allied to the 
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abstinence/recovery philosophy. This respondent noted that there were “four main 
stakeholders, the four charities that grew on the back of Government treatment 
money.” The allocation of government money was linked with the fact that the 
existing approach, substitution treatment, was protected by powerful authority figures 
in government and in the House of Lords who “had never advocated rehab.”; this 
made it “very difficult to get a policy shift unless you get a budget shift”. 
Nevertheless, during this phase of policy, the numbers of stakeholders involved in 
drug treatment policy expanded to include a diverse mix including medical 
professionals, statutory services, voluntary organisations, universities, private 
companies, drug action teams, primary care trusts, specialist treatment services, 
general practices, nursing teams, mental health groups, prisons, probation, drug user 
groups, social enterprises, and pharmaceutical companies (Mold, 2008). This 
expansion was the result of more resources being made available for drug treatment, 
particularly via the criminal justice system, as well as the increase in methadone 
prescribing as a key tool in crime reduction (Duke, 2006). There was a new drive to 
include service user groups in policy making circles from the late 1990s, for instance, 
the Experts by Experience programme established in 2003 by the NTA (see Mold and 
Berridge, 2010, pp. 149-150).  These groups began to provide evidence to expert 
committees and „lay knowledge‟ began to be viewed as „evidence‟.  These 
developments are indicative of increasing both representation and participation in the 
science-policy nexus.  A greater range of stakeholders, including user groups, were 
invited to participate and contribute to the debates surrounding drugs issues. At the 
same time, others still felt excluded; they saw their exclusion as a reflection on their 
policy position and on the lack of evidence which would be credible in policy circles: 
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“I gave up with the NTA…once  this Government got in, XX invited me in, 
which was very nice…. I‟d always been treated as some sort of  -   well not 
quite persona non grata, but someone that didn‟t understand what was 
happening … I was beyond the pale basically I think.” The respondent went on 
“If I had all the money in the world, I could generate a whole load of useful 
evidence to back up my policy ideas, do you know what I mean?”                                                                                                                               
However, from 2005, substitution treatment became re-defined as a „problem‟ in itself 
(Duke et al, 2013). Evidence from existing research underwent subtle re-interpretation 
to focus on exit from treatment rather than on harm reduction gains and formerly 
excluded voices began to find a window of opportunity for their views. Research 
evidence and treatment outcome data was used by some stakeholders to argue that 
methadone maintenance prescribing was failing to help individuals become „drug 
free‟ and exit the treatment process. New forms of evidence and discourse began to 
penetrate the policy debate. The right wing Conservative think tank, the Centre for 
Social Justice, drew on selected pieces of research and argued that the whole 
treatment system required reform and that abstinence based treatment was the way 
forward (Centre for Social Justice, 2007). Quantitative survey research indicated that 
the treatment goal for many drug users was abstinence rather than prolonged 
maintenance prescribing (McKeganey et al, 2004). One researcher described how this 
research was used as „ammunition‟ by recovery groups and politicians:  
“That was tremendous ammunition to recovery groups, the politicians...they 
could say look this is what the patients want....that was a case of very 
questionable research asking an extremely leading question of people coming 
to a door which says abstinence based treatment service....of course they are 
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going to say abstinence...So this very questionable finding was used....they 
took what they wanted from them to justify their positions and ignored the rest 
or didn‟t ask the questions.” 
The media also became involved in the construction of the „methadone problem‟ in 
2005. Using NTA statistics, the British Broadcasting Corporation (BBC) reporter, 
Mark Easton, reported that only 3% of drug users had exited treatment „drug free‟, 
meaning free from substitution drugs such as methadone.  This particular reading and 
interpretation of the statistics became the focus of heated debate.  This provided an 
opportunity for some stakeholders who wanted to break the harm reduction consensus 
to influence the direction of policy towards an abstinence based framework. This 
external threat to the established harm reduction consensus was important as it helped 
to facilitate a shift within the final drug strategy published by the Labour government 
in 2008 (HM Government, 2008).   The focus of this strategy was on ensuring drug 
users exit treatment and reintegrate back into society. 
Research published later began to highlight the shortcomings of treatment sessions 
which focused primarily on prescription and testing issues rather than counselling and 
therapy (Best et al., 2010).   However, further qualitative research with recovering 
heroin users conducted by Neale et al. (2011) highlighted the importance of asking 
what drug users meant when they said they wanted to be abstinent.  For example, they 
might not mean abstinence from all drugs and they might want to continue with harm 
reduction for a period before moving towards abstinence.  Moreover, the research 
revealed that drug users have broader treatment goals which extend beyond their drug 
consumption including improved personal relationships, engaging in meaningful 
activities and improved mental and physical health.  
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McKeganey (2012) notes the changing narrative around the use of methadone in 
drugs treatment from 2005 onwards and the use of the „methadone parking lot‟ 
metaphor.  Methadone shifted from being seen as a highly effective treatment to a 
failing treatment.  Despite the lack of „hard data‟ on the actual time individuals had 
been prescribed methadone, this imagery of drug users being „parked‟ on methadone 
was powerful (McKeganey, 2012).  Similarly another researcher (interviewee) argued 
that there was a backlash against the accumulated scientific evidence base which 
showed that treatment worked: 
“...there is really a lack of evidence...what‟s interesting about the backlash is 
that all this scientific evidence which showed that treatment worked, was 
thrown out of the window and back to anecdote and slogan, these dreadful 
slogans, „parked on methadone‟ and so on. People being zombies in the 
clinics, I mean dreadful language. So very non scientific and a highly 
contentious debate.”   
Other stakeholders also had this view regarding the move away from scientific 
evidence, including one of the representatives from a user organisation: 
“one of the good things about the last ten years...the clinical side of things was 
actually based on evidence and a lot of evidence that was backed up and the 
same evidence is still there to this day, which backs up Methadone as the gold 
standard of the treatment of heroin addiction...now there seems to be a 
worrying turn away from the evidence and to look at things where there is no 
evidence base...The biggest change since the Coalition (government) is to 
ignore evidence or going back to ignoring advice from the ACMD (Advisory 
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Council on the Misuse of Drugs). It seems that politicians think they know best 
and they don‟t actually need experts or anyone to advise them”   
However, some researchers saw the lack of research devoted to the question of 
aftercare in Britain as problematic.  This left a huge gap in the evidence base and no 
alternative to the evidence surrounding the efficacy of methadone.  There was little 
research which had tracked those who had „recovered‟ successfully from drug 
problems:  
 “I couldn‟t find anything anyone in Britain had done about what happens to 
people who get better. Does anyone get better?  Do we have contact with 
them?  And the answer was pretty much they were either disbelieved about 
whether they got better or they were ignored.  So essentially what we‟d done 
was we had created a science of pessimism.”  (interview with researcher). 
Relating back to Backstrand‟s dimensions of civic science, we see greater 
participation of different interest groups (including user groups) in the debates 
surrounding the evidence on substitution treatment during this phase.   There were 
also attempts to ensure greater representation of different forms of evidence and 
perspectives within the deliberations. However, these different forms of evidence 
were used in directly political ways.  Neale (2013, p. 1059) argues that this period was 
characterised by a „cynical manipulation of research findings: a triumph of politics 
and ideology over science and scholarship‟.  
 
Re-affirming the importance of ‘scientific’ evidence and expertise 
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In the lead up to the general election in May 2010, the debate regarding the goals of 
drug treatment policy and the place of substitute prescribing continued to rage.  The 
concept of „recovery‟ and how it could be defined began to take hold within the 
treatment debates.  This was aided by international and national policy frameworks as 
well as key international experts and policy entrepreneurs who advocated a recovery 
position (see White, 2007).  For example in the United States, the Betty Ford Institute 
Consensus Panel (2007) consisting of researchers, policy makers, clinicians and 
members of the recovering community held a conference to discuss the definition of 
recovery and how it could be measured.  This included the influential recovery 
advocate William White as well as Dr Thomas McLellan, who was the Deputy 
Director of the White House Office of National Drug Control Policy from 2009 to 
2010.  They defined recovery as „a voluntarily maintained lifestyle characterised by 
sobriety, personal health and citizenship‟ (Betty Ford Institute Consensus Panel, 2007, 
p. 222).  This work was influential in the UK and led to a similar exercise under the 
auspices of the United Kingdom Drug Policy Commission (UKDPC) drawing on the 
knowledge of key international experts.  As one UK expert recalls: 
“We did that in a more modest way than they had done in the States, but we 
involved Tom McLellan from the States who very generously came over and 
helped us with that exercise, and it led to UKDPC doing a report about 
recovery, trying to reconcile probably the two big stakeholders within that - 
the Twelve Step Abstinence territory and then there was also methadone 
maintenance treatment providers and recipients.” 
The development of this Consensus statement in the UK drawing on the American 
panel‟s work represents a type of policy or „ideas‟ transfer. The influence for a 
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recovery based policy also came from Scotland where they had already adopted this 
type of strategy.  In 2008, the Scottish government put forward a new drug strategy 
entitled: „The Road to Recovery: a new approach to tackling Scotland‟s drug 
problem‟ (The Scottish Government, 2008). However, this strategy, drawing 
substantially on insights from the mental health field, adopted a broader definition of 
recovery following the statement that, “recovery may not involve abstinence – all 
services and commissioning partners must put service users at the heart of their 
activities” (Scottish Advisory Committee on Drug Misuse, 2008, p4).  
As the election approached, „recovery‟ had been successfully embedded within policy 
and practice discussions although, as one researcher commented there was still an  
“uneasy relationship between those who are defining drug use as a medical 
problem for which medical intervention is needed and those who define drug 
use as elements of a lifestyle which needs intervention from a wider range of 
professional and non-professional groups.”  
Despite various attempts to reach consensus around the term „recovery‟ and the ways 
in which it would be measured, it was not explicitly defined within the new drug 
strategy of the Conservative/Liberal Democrat Coalition government (HM 
Government, 2010).  This was a key tactic to temper the debate and calm the field 
(Duke et al, 2013).  However, in order to settle the debates around the future role of 
substitution treatment within the new drug strategy, the NTA appointed Professor 
John Strang, a leading addiction psychiatrist, to chair an expert group which would 
examine the evidence base for different forms of substitute prescribing.  This would 
include the hotly debated issue of time limited prescriptions. The expert group 
included stakeholders from a wide range of different professional backgrounds and 
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ideological positions (NTA, 2012b) - psychiatrists, researchers, physicians, 
psychologists, nurses, commissioners, representatives from advocacy organisations 
(carer/families of users), service directors, service users, and representatives from 12 
steps and residential rehabilitation sectors.  It is clear that the different stakeholders 
were chosen carefully to ensure that a wide range of perspectives were represented.  
However, the degree of „real‟ participation by some members was questioned. Some 
of the stakeholders we interviewed saw the group as representing the „old world 
order‟ ie. dominated by „doctors‟ and organised by the NTA.  As one researcher 
argued: 
“One of the interesting things is how disenfranchised many of the people who 
would regard themselves as community recovery people felt and fell from that 
group...This was the „old world order‟ of the way the NTA did things.  In 
direct contrast to that was the Recovery Group UK with a very different 
supposedly much more of a grass roots level of representation.”  
The goals of the expert group were to develop a clinical consensus and appropriate 
clinical protocols for opioid substitution treatment (OST) which support long-term 
recovery and prevent „unplanned drift into long-term maintenance‟ and to develop a 
model for „segmentation‟ of the treatment population and suitable treatment 
placement indicators, both in the context of the developing treatment framework‟ 
(NTA, 2011, p. 8). The expert group was supported by an international advisory 
group including a member from the Cochrane Drugs and Alcohol Group (Dr Laura 
Amato), a key researcher from Australia (Professor Wayne Hall), and recovery 
advocates from the United States (Professors Keith Humphreys, Thomas McLellan 
and William White).  This international dimension was seen to be important by key 
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members of the group in terms of „tying into this international scientific objectivity 
mindset...the reason for having the group was to connect with that wider 
constituency‟.  (interview with member of the expert group) 
The „scientific‟ evidence was fundamental to the work of the expert group.  A key 
task was to review the national and international evidence on OST and its 
effectiveness.  The work of the expert group was to be underpinned by scientific 
objectivity and rigour.  As one member of the expert group put it, they wished to 
„avoid the abuse of science, where you just cherry pick it for things that support your 
prejudices.‟  The review of the evidence attempted to „integrate, as far as is possible, 
the discourse of evidence-based practice (built on observation and measurement), 
with the humanitarian, recovery-based discourse based on values (such as 
responsibility, choice and empowerment) and [it] identifies where the optimism which 
is central to recovery discourse needs to be tempered with evidence, and where the 
energy and focus on self-improvement associated with recovery can enhance the 
effectiveness of evidence-based practice.‟ (NTA, 2012b, Appendix C p. 1).  This 
suggests an attempt at fusing or merging the traditional „scientific‟ evidence with 
other forms of „non-scientific‟ evidence.  The starting point of the review however 
was the empirical evidence on the effectiveness of OST and the factors associated 
with treatment effectiveness based on Cochrane criteria.  A secondary aspect was to 
explore „where the insights and dynamism of recovery can enhance effectiveness of 
treatment (NTA, 2012b, Appendix C, p. 1).  Although this represents a break from the 
norm, the adherence to the hierarchy of evidence (ie the dominance of RCT studies) is 
apparent in the review. 
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Some of the stakeholders we interviewed viewed these developments as maintaining 
the status quo, evidence of the continued dominance of psychiatry in addiction and the 
„professionalization‟ of recovery. The final report of the expert group concluded that 
OST should continue to have „an important and legitimate place within recovery-
orientated systems of care‟ (NTA, 2012b, p. 5).  Although the value of OST with no 
time limits was emphasised, they recommended a more rigorous and ambitious 
system of monitoring, review and assessment of those on prescriptions in order to 
check and stimulate their readiness to change and to use and develop their recovery 
capital. Best and Laudet (2010: 2) define recovery capital as „the sum of resources 
necessary to initiate and sustain recovery from substance misuse‟. Recovery capital 
can be broken down into four types: social, physical, human, and cultural (see Cloud 
and Granfield, 2008). Within a recovery-orientated treatment system, the expert group 
concluded that a full range of treatment interventions are required and emphasised 
that treatment services cannot operate in isolation from other support such as 
employment, training and housing.   
In conclusion, it is clear that the use of „scientific‟ evidence was of paramount 
importance to their conclusions, as was the endorsement of the international network 
of experts.  The lack of focus on other non-medication aspects of the recovery arena 
was a direct result of the brief given to the expert group at the beginning of the project 
which was to examine the relationship between medications and recovery. This 
emphasises the influence of those who establish national advisory or expert groups 
over the inclusion or exclusion of bodies of evidence and illustrates how parameters 
are set which tend to perpetuate the types of evidence and science which are given 
legitimacy and credibility in policy and practice debates.  In comparison to the strong 
Page 25 of 32
Ac
ce
pte
d M
an
us
cri
pt
24 
 
evidence base demonstrating the effectiveness of OST, there is a paucity of research 
on the different aspects of „recovery‟ and other forms of treatment and support. Much 
of the existing research in these areas is not considered „scientific‟.  As one of the 
representatives from an advocacy organisation argued in relation to the evidence base 
on residential rehabilitation:   
“The ones I know who have gone to the Lee or Providence Projects or up at 
Phoenix Adult Residential – they stay, they create a new network, a new 
environment.  That‟s evidence based, but it‟s not the evidence that the 
Department of Health is interested in.  It‟s not the evidence that NICE 
(National Institute for Health and Care Excellence) is interested in. They are 
interested in RCTs for methadone”.  
Leighton (2013) argues that there is discontent in the drug and alcohol fields 
regarding psycho-social interventions and complex social programmes (ie therapeutic 
communities and mutual help/aid).  The key problem is that these types of 
interventions do not have causal powers in themselves, rather the causes of change in 
participants are processes of changing reasoning and are dependent on wider social 
and cultural features.  Although the literature on the mechanisms behind these 
interventions has been accumulating, it has been pushed aside in favour of the 
evidence generated from RCTs. As this study, along with other work has illustrated, 
some forms of evidence have succeeded in accumulating greater credibility, 
legitimacy and authority than other forms (Gieryn, 1995) and, as we have argued 
above, due to their powerful location within established policy and bureaucratic 
systems, they are difficult to oppose.  
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Conclusion 
As in other policy spheres, drugs policy is shaped by a number of competing 
influences including politics, ideologies, values, the media, perceived public opinion 
and pragmatic constraints such as funding (Ritter, 2009; MacGregor, 2011; 2013; 
Stevens, 2011; Monaghan, 2011).  As we have seen, these are reflected in the 
discourses and policy demands of different stakeholder groups – different treatment 
professionals and occupational groups, user groups, bureaucrats representing different 
government departments, NGO‟s and researchers. Even those working as experts 
within the core of the policy bureaucracy are not always successful in promoting their 
preferred policy option despite the nature of the available evidence. One example 
which illustrates the competing influences and pressures on government was the 
dismissal of the Chairman of the Advisory Council on the Misuse of Drugs (ACMD) 
in October 2009 because he was deemed to have crossed the line from science to 
policy (Nutt, 2012). On this occasion, the expert and his translation of the evidence 
was not acceptable within the existing framework of understanding (and policy) 
around drugs. While this challenge came from within the policy bureaucracy, from the 
analyses above, it is clear that there has also been a challenge to the top down model 
of „scientific evidence‟ and expertise.  
There has been some shift away from belief in the knowledge-driven model where the 
expert – and research-derived evidence – is granted a central role in policy 
consideration, towards the enlightenment model where research is separate from 
policy making and policy is evidence informed, rather than evidence based, thus 
granting a less powerful, less determining role to expert advice (Young et al., 2002). 
We have illustrated attempts at greater representation of different forms of evidence 
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and participation by an increasing number of stakeholders, including user groups, in 
the treatment debates in England.  However, as Backstrand (2004b, p. 709) argues, 
representation and participation do not necessarily lead to democratisation of science: 
“the experiments of citizen participation do not necessarily amount to democratic 
governance of science.  In some instances, the turn to public participation represents 
cosmetic adjustment that does not challenge trenchant policy techniques.” As we have 
noted, in some policy domains, the notion of full citizen participation may be 
unrealistic, although the expansion of stakeholder groups within new networks of 
governance opens up opportunities for wider representation and participation at least 
among relevant professional and policy relevant groups.  
This case study of debates surrounding opioid substitution treatment policy illustrates 
that the drugs field in England is only beginning to grapple with representation and 
participation; moreover, there seems to have been a limited „window‟ for these 
processes to emerge and develop. The case study has highlighted the close 
relationship between what is perceived and accepted as policy relevant evidence and 
how that form of evidence becomes firmly embedded within dominant policy 
structures and systems. As an integral part of established systems, supported by 
powerful stakeholders, the evidence itself becomes the basis for attracting resources 
and extending the evidence base, thus making it less likely that challenges will be 
successful.  
Given the recent shift towards recovery within English drugs policy, a key question is 
what will be the role of the various different forms of „evidence‟ and use of „experts‟ 
in the shaping of the implementation and evaluation of the policy?   With the 
economic recession and public sector funding cuts, funding for „scientific‟ research is 
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likely to be affected.  Will different forms of „evidence‟ and expertise be used more in 
the policy debates and decision making? Research on „recovery‟ lends itself to 
qualitative and participatory methodologies, but will these types of studies be funded 
by the research councils and government departments in England when, with the 
Payment by Results initiative (ie. where drug agencies are paid only for „successful‟ 
outcomes in treatment), there continues to be an obsession with outcomes and with 
measuring „recovery‟. The indication from this case study is that new governance 
structures will strive to adopt a rational-knowledge driven model of the policy-
evidence relationship despite awareness of a much more complex picture of the role 
of science and the expert in policy.  
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